Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter

Abstract Background Catheter ablation (CA) for atrial fibrillation (AF) and atrial flutter (AFL) is contraindicated is left atrial thrombus (LAT) is found. The present registry aims to provide a contemporary estimate of LAT prevalence and to identify potential subsets of patients at higher risk. Methods All consecutive patients undergoing TOE before AF/AFL CA were enrolled between January 2019 and April 2024. Inclusion criteria were AF/AFL with less than 3 weeks optimal OAT, persistent or paroxysmal AF/AFL with CHA2DS2-VASc≥2. Risk factors associated with LAT were tested by regression analysis. Results 586 patients were enrolled (age 66±6 years; 72% males and 14 thrombi (2.4%), located in the left atrial appendage. Patients with LAT had a higher prevalence of coronary artery disease (CAD), heart failure (HF), and persistent AF (11 vs 3 patients, p = 0.048) as well as lower left ventricular ejection fraction (56 vs 49%, p = 0.01) and higher systolic pulmonary artery pressure (34 vs 29 mmHg, p = 0.028). No difference was found in patients according to adherence to oral anticoagulant therapy, left atrial echocardiographic characteristics or renal function. No LAT was found in patients with atrial flutter. According to univariate analysis (figure 1), CAD and HF were identified as predictors of LAT formation. LEVF was analyzed with a receiving operator characteristic curve (ROC) with an area under the curve (AUC) of 0.752 (95% CI 0.629-0.875; p=0.001) with the best cut-off at 50%. Moreover, LVEF less than 50% is a predictor of thrombi with an HR of 8.81 (95% CI; 2.89-26.87; p=0,001). Based on our data, we propose a protocol for TOE before CA in patients with AF as seen in Figure 2. Conclusions LAT is a rare occurrence in candidates for CA. Patients with persistent AF, history of CAD or HF present an elevated risk and should be considered for TOE prior to CA. Patients with AFL and no structural disease have an extremely low risk of LAT.Univariate table Proposed protocol

Authors

Institutions

Publication Details

Journal
EP Europace
Published
2025-05-01
DOI
https://doi.org/10.1093/europace/euaf085.486
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter

Lorenzo Torselletti, Federico Guerra, Francesca Coraducci, Cristina Gatti et al.
EP Europace
Atrial Fibrillation Management and Outcomes
article

Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter

Lorenzo Torselletti, Federico Guerra, Francesca Coraducci, Cristina Gatti, Paolo Compagnucci, Alessandro Barbarossa, Giulia Stronati, Michela Casella, Antonio Dello Russo, Samuele Principi, T Gaudenzi
article en

Abstract

Abstract Background Catheter ablation (CA) for atrial fibrillation (AF) and atrial flutter (AFL) is contraindicated is left atrial thrombus (LAT) is found. The present registry aims to provide a contemporary estimate of LAT prevalence and to identify potential subsets of patients at higher risk. Methods All consecutive patients undergoing TOE before AF/AFL CA were enrolled between January 2019 and April 2024. Inclusion criteria were AF/AFL with less than 3 weeks optimal OAT, persistent or paroxysmal AF/AFL with CHA2DS2-VASc≥2. Risk factors associated with LAT were tested by regression analysis. Results 586 patients were enrolled (age 66±6 years; 72% males and 14 thrombi (2.4%), located in the left atrial appendage. Patients with LAT had a higher prevalence of coronary artery disease (CAD), heart failure (HF), and persistent AF (11 vs 3 patients, p = 0.048) as well as lower left ventricular ejection fraction (56 vs 49%, p = 0.01) and higher systolic pulmonary artery pressure (34 vs 29 mmHg, p = 0.028). No difference was found in patients according to adherence to oral anticoagulant therapy, left atrial echocardiographic characteristics or renal function. No LAT was found in patients with atrial flutter. According to univariate analysis (figure 1), CAD and HF were identified as predictors of LAT formation. LEVF was analyzed with a receiving operator characteristic curve (ROC) with an area under the curve (AUC) of 0.752 (95% CI 0.629-0.875; p=0.001) with the best cut-off at 50%. Moreover, LVEF less than 50% is a predictor of thrombi with an HR of 8.81 (95% CI; 2.89-26.87; p=0,001). Based on our data, we propose a protocol for TOE before CA in patients with AF as seen in Figure 2. Conclusions LAT is a rare occurrence in candidates for CA. Patients with persistent AF, history of CAD or HF present an elevated risk and should be considered for TOE prior to CA. Patients with AFL and no structural disease have an extremely low risk of LAT.Univariate table Proposed protocol

EP EuropaceVol. 27(Supplement_1)
Marche Polytechnic University (IT), Ospedali Riuniti di Ancona (IT)
Openalex Percentile: Top 79%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.